🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT05069558
Active, not recruiting Not applicable

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

NCT05069558 · tracked via the Priya Life Science UK tracker
Sponsor
Occlutech International AB
Phase
Not applicable
Started
2022-05-09
Last updated
2026-05-22

Condition(s) studied

StrokePatent Foramen OvalePFO

Investigational drug(s) / intervention(s)

Investigational PFO Closure DeviceStandard of Care PFO Closure Device

Investigational PFO Closure Device: Occlutech Flex II PFO Closure Device

Standard of Care PFO Closure Device: Amplatzer PFO Occluder and Gore Cardioform PFO Occluder

Study summary

The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: Subjects with a PFO and cryptogenic stroke: * PFO defined as visualization of microbubbles (during Trans Esophageal Echo (TEE)) in the left atrium within three cardiac cycles of right atrial opacification at rest and/or with Valsalva. * Cryptogenic stroke defined as a stroke of unknown cause. * Stroke defined as an acute focal neurological deficit, presumed to be due to focal ischemia, and either: * Symptoms persisting ≥24 hours OR * Symptoms persisting \<24 hours with Magnetic Resonance Imaging (MRI) or Computer Tomography (CT) findings of a new, neuroanatomically relevant, cerebral infarct. Exclusion Criteria: * Age \< 18 years * Myocardial Infarction (MI) or unstable angina within 6 months. * Severe mitral valve stenosis, severe aortic valve stenosis, or severe regurgitation. * Left Ventricle Ejection Fraction (LVEF) \<35%. * Uncontrolled hypertension or diabetes mellitus despite medications. * Subjects contraindicated for aspirin or clopidogrel. * Presence of other comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results. * Qualifying stroke with Modified Rankin score \>3. * Anatomy in which the device would interfere with intracardiac or vascular structures. * Life expectancy \< 2 years. * Participation in another clinical study that can interfere with the results of this study * Exclusion for patients with known causes of ischemic stroke: * Atrial fibrillation/atrial flutter (chronic or intermittent). * Left Ventricle (LV) aneurysm, intracardiac thrombus, or tumor. * Mitral or aortic valve vegetation or prosthesis. * Aortic arch plaques protruding \>4 mm into the lumen. * Atherosclerosis or arteriopathy of intra- or extracranial vessels with \>50% diameter stenosis in the artery supplying the infarcted territory. * Another cause of right-to-left shunting (e.g., an Atrial Septal Defect (ASD) or a fenestrated atrial septum). * Presence of an arterial hypercoagulable state. * Lacunar infarct probably due to intrinsic small vessel as the qualifying event, defined as an ischemic stroke in the distribution of a single, small deep penetrating vessel in a patient with any of the following: * A history of hypertension (except in the first week post stroke). * A history of diabetes mellitus. * Age ≥50 years. * MRI or CT with leukoaraiosis greater than symmetric, well-defined periventricular caps, or bands (European Task Force on Age-Related White Matter Changes rating scale score \>0). * Arterial dissection as the qualifying event.

Primary outcome measure(s)

Trial sites (48)

FacilityCityRegionStatus
Arizona Cardiovascular Research Center Phoenix Arizona
Stanford University Medical Center Stanford California
Los Robles Medical Center Thousand Oaks California
Colorado Heart and Vascular PC / St. Anthony Hospital Lakewood Colorado
South Denver Cardiology Associates Littleton Colorado
Medstar Washington Hospital Center Washington D.C. District of Columbia
Rush University Medical Center Chicago Illinois
OSF Saint Francis Medical Center Peoria Illinois
University of Louisville Louisville Kentucky
MaineHealth Portland Maine
Tufts New England Medical Center Boston Massachusetts
Massachusetts General Hospital Boston Massachusetts
Beth Israel Deaconess Medical Center Boston Massachusetts
Baystate Medical Center Springfield Massachusetts
University of Michigan Ann Arbor Michigan
Essentia Health Duluth Minnesota
University of Nebraska Medical Center Omaha Nebraska
The Valley Hospital Paramus New Jersey
University Hospitals Cleveland Medical Center Cleveland Ohio
The Ohio State University Columbus Ohio
Ohio Health Research Institute Columbus Ohio
Oklahoma Heart Hospital Oklahoma City Oklahoma
Oregon Health & Science University Portland Oregon
UPMC Presbyterian Pittsburgh Pennsylvania
Vanderbilt Medical Center Nashville Tennessee
HCA Houston Healthcare Medical Center Houston Texas
University of Texas Health Science Center at Houston Houston Texas
University of Alberta Mazankowski Heart Institute Edmonton Alberta
Vancouver General Hospital Vancouver British Columbia
Ottawa Heart Institute Ottawa Ontario
Toronto General Hospital Toronto Ontario
Centre Hospitalier de l'Université de Montreal (CHUM) Montreal Quebec
Institut de Cardiologie de Montréal Montreal Quebec
Aarhus University Hospital Aarhus Denmark
Rigshospitalet Copenhagen Copenhagen Denmark
Heart and Lung Center, Helsinki University Hospital Helsinki Finland
CHU Grenoble Alpes La Tronche France
Hôpital Privé Jacques Cartier Massy France
CHU Toulouse Rangueil Toulouse France
Universitaetsklinikum Hamburg-Eppendorf Hamburg Free and Hanseatic City of Hamburg

+ 8 more sites — see the full list on the official registry below.

More Occlutech International AB trials in the UK

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05069558 on ClinicalTrials.gov ↗ ← All trials in the UK